Oncternal Therapeutics announces updated data from Phase 1/2 study of ONCT-534
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 22 2024
0mins
Study Overview: Oncternal Therapeutics provided updated data from its Phase 1/2 study of ONCT-534 for treating relapsed or refractory metastatic Castration-Resistant Prostate Cancer (mCRPC), incorporating additional dosing cohorts with twice daily administration, which showed good tolerance and no severe toxicities.
Patient Response: One patient demonstrated a significant reduction in PSA levels after increasing the dosage, while biomarker analysis indicated promising effects on tumor cell characteristics, although some patients exhibited neuroendocrine features linked to AR-independent disease progression.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
